A multicenter prospective randomized trial of corticosteroids in primary therapy for Kawasaki disease: clinical course and coronary artery outcome

J Pediatr. 2006 Sep;149(3):336-341. doi: 10.1016/j.jpeds.2006.05.025.

Abstract

Objective: To investigate the role of corticosteroids in the initial treatment of Kawasaki disease (KD).

Study design: Between September 2000 and March 2005, we randomly assigned 178 KD patients from 12 hospitals to either an intravenous immunoglobulin (IVIG) group (n = 88; 1 g/kg for 2 consecutive days) or an IVIG plus corticosteroid (IVIG+PSL) group (n = 90). The primary endpoint was coronary artery abnormality (CAA) before a 1-month echocardiographic assessment. Secondary endpoints included duration of fever, time to normalization of serum C-reactive protein (CRP), and initial treatment failure requiring additional therapy. Analyses were based on intention to treat.

Results: Baseline characteristics of groups were similar. Fewer IVIG+PSL patients than IVIG patients had a CAA before 1 month (2.2% vs 11.4%; P = .017). The duration of fever was shorter (P < .001) and CRP decreased more rapidly in the IVIG+PSL group than in the IVIG group (P = .001). Moreover, initial treatment failure was less frequent (5.6% vs 18.2%; P = .010) in the IVIG+PSL group. All patients assigned to the IVIG+PSL group completed treatment without major side effects.

Conclusions: A combination of corticosteroids and IVIG improved clinical course and coronary artery outcome without causing untoward effects in children with acute KD.

Publication types

  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • Child
  • Child, Preschool
  • Coronary Aneurysm / chemically induced
  • Coronary Aneurysm / diagnostic imaging
  • Coronary Aneurysm / prevention & control*
  • Drug Therapy, Combination
  • Female
  • Glucocorticoids / administration & dosage*
  • Glucocorticoids / adverse effects
  • Humans
  • Immunoglobulins, Intravenous / administration & dosage*
  • Immunologic Factors / administration & dosage*
  • Infant
  • Male
  • Mucocutaneous Lymph Node Syndrome / diagnostic imaging
  • Mucocutaneous Lymph Node Syndrome / drug therapy*
  • Prednisolone / administration & dosage*
  • Prednisolone / adverse effects
  • Prospective Studies
  • Treatment Outcome
  • Ultrasonography

Substances

  • Glucocorticoids
  • Immunoglobulins, Intravenous
  • Immunologic Factors
  • Prednisolone